Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoid tumour; Pancreatic cancer
- Focus Therapeutic Use
- 23 Jan 2019 Planned End Date changed from 16 Aug 2020 to 16 Aug 2021.
- 23 Jan 2019 Planned primary completion date changed from 16 Aug 2019 to 16 Aug 2020.
- 23 Jan 2019 Status changed from recruiting to active, no longer recruiting.